DexCom (DXCM) Tops Q1 EPS by 3c

DexCom (NASDAQ: DXCM) reported Q1 EPS of $0.33, $0.03 better than the analyst estimate of $0.30. Revenue for the quarter came in at $505 million versus the consensus estimate of $484.23 million.

“Dexcom is off to a great start in 2021, including several key advancements of our strategic priorities in the first quarter,” said Kevin Sayer, Dexcom’s chairman, president and CEO. “Based on the strength of our first quarter results and the significant market opportunity ahead of us, we are pleased to raise our 2021 revenue guidance.”

GUIDANCE:

DexCom sees FY2021 revenue of $2.26-2.36 billion, versus the consensus of $2.32 billion.

For earnings history and earnings-related data on DexCom (DXCM) click here.

You May Also Be Interested In

• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c
• Dexcom Further Advances Vision of Glucose Biosensing for All
• Paychex beats fourth quarter EPS estimates, stock slides